ICIs—such as programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)—have shown remarkable efficacy in treating malignancies, including hepatocellular carcinoma (HCC) and melanoma [1]. This evidence concerns the gene CTLA4 and melanoma.